With 1.08 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $30.84 whereas the lowest price it dropped to was $30.05. The 52-week range on ZLAB shows that it touched its highest point at $36.60 and its lowest point at $13.48 during that stretch. It currently has a 1-year price target of $51.24. Beta for the stock currently stands at 1.04.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZLAB was down-trending over the past week, with a drop of -5.90%, but this was up by 23.72% over a month. Three-month performance surged to 72.68% while six-month performance rose 87.45%. The stock gained 23.07% in the past year, while it has gained 11.45% so far this year. A look at the trailing 12-month EPS for ZLAB yields -3.07 with Next year EPS estimates of -1.82. For the next quarter, that number is -0.78. This implies an EPS growth rate of 13.14% for this year and 39.32% for next year.
Float and Shares Shorts:
At present, 99.12 million ZLAB shares are outstanding with a float of 98.53 million shares on hand for trading. On 2024-10-15, short shares totaled 4.75 million, which was 476.99999999999994 higher than short shares on 1726185600. In addition to Dr. Ying Du Ph.D. as the firm’s Founder, Chairperson & CEO, Mr. Joshua L. Smiley serves as its President & COO.
Institutional Ownership:
Through their ownership of 0.50525004 of ZLAB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, ZLAB reported revenue of $100504000.0 and operating income of -$75530000.0. The EBITDA in the recently reported quarter was -$72736000.0 and diluted EPS was -$0.8.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZLAB since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
